Although, the role of GPRC5 has recently been associated with dormant HSCs, where it acts by mediating ATRA action by restricting the protein translational rate and ROS levels [67]; to our knowledge, this is the first report where changes in GPRC5C gene expression have been associated to CML. This evidence concerns the gene GPRC5C and chronic myelogenous leukemia, BCR-ABL1 positive.